News 22.07.21

Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company.

Read more
News 21.07.21

Citryll announced that it has recently secured three grant of patents

Citryll is pleased to announce that it has recently secured grant of patents in China (in March 2021), in Australia (in May 2021), and in the USA (in July 2021) relating to the use of therapeutic Anti-Citrullinated Protein Antibodies (tACPAs) to treat one of our lead indications, idiopathic pulmonary fibrosis (IPF).

Read more
News 19.07.21

PharmaCytics submitted 3 new patents

PharmaCytics has submitted 3 new patents to support their Nutrient Drug Conjugate-technology (NDCt). It shows the continuous commitment to develop our ground-breaking Nutrient Drug Conjugate technology. The patents cover new nutrient drug conjugates and new linker technologies. All patents will support the work of PharmaCytics ultimately benefiting patients by making drugs more effective.

Read more
News 15.07.21

Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands

In partnership with GHO Capital, ARDENA announced a major €35 million investment for expansion across its European operations. The investment will future proof offerings for the biopharma and emerging biotechnology sectors and positions Ardena to become a leading global CDMO, offering end-to-end solutions spanning the full pharma development lifecycle.

Read more
News 13.07.21

PimBio: €0,5M for iPSC-based NMJ-on-a-chip model

PimBio is proud to announce that our NOACH (NMJ-On-A-CHip) consortium under the supervision of Dr. Maartje Huijbers has received a LUMC PPS-Match call Topsector LSH 2021 funding for the development of a patient-derived iPSC-based NMJs-on-a-chip model to study NMJ (patho)physiology by combining functional parameters with a relevant human genetic background.

Read more
News 13.07.21

Inprocess-lsp and DIANT Pharma Inc. finalize Partnership Agreement

DIANT Continuous Nanoparticle Manufacturing System Integrates With InProcess-LSP NanoFlowSizer For Size Characterization. DIANT Pharma Inc. (DIANT), a startup company that provides a turnkey solution for continuous manufacturing of nanoparticles, has the exclusive right to integrate the NanoFlowSizer into the DIANT system, providing a major advantage to DIANT customers. The DIANT system has multiple flow options, up to 100 LPM, and has multiple add-on modules with integrated process analytical technology operating as a single, closed-system.

Read more
News 12.07.21

Citryll enters into bioanalytics partnership with Ardena

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).

Read more
News 05.07.21

Bioconnection: GMP certification for new large scale filling line

BioConnection received from the Dutch Healthcare Inspectorate (IGJ) the GMP certification and manufacturing license for their new large scale filling line

Read more
News 16.06.21

Commercial Agency Agreement between Ardena and South Korean company Keyfronbio Co., Ltd.

Ardena is pleased to announce that a Commercial Agency Agreement for South Korea has been signed with the company Keyfronbio Co., Ltd.

Read more